SeaStar Medical is trading up 10.96% at $2.43 after the FDA confirmed on November 3, 2026, that the required post-approval study for its pediatric QUELIMMUNE therapy is complete. - The decision removes the registry’s research-infrastructure requirement, potentially allowing more hospitals to offer the treatment to critically ill children. - GlobeNewswire carried the announcement, which was reported the same morning; no current volume figure was supplied.